Inogen (NASDAQ:INGN) Share Price Passes Below Two Hundred Day Moving Average - Here's Why

Key Points

• Inogen shares fell below their 200-day moving average, trading as low as $5.33 versus the $6.35 average, and last changing hands near $5.37.
• The company posted a quarterly loss of $0.14 per share, slightly outperforming estimates, while revenue of $95.08 million narrowly missed expectations. Inogen remains unprofitable, with a negative net margin and analysts projecting a full-year loss.
• Analyst sentiment is mixed, ranging from “Strong Buy” to “Sell,” while Weiss Ratings reiterated a “Sell” rating. Institutional investors own nearly 90% of the stock, although an executive recently sold 68.46% of her holdings.

Inogen, Inc (NASDAQ:INGN - Get Free Report)'s share price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $6.35 and traded as low as $5.33. Inogen shares last traded at $5.37, with a volume of 306,551 shares.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of Inogen in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Inogen presently has an average rating of "Moderate Buy".

Inogen Price Performance

The stock has a market cap of $142.52 million, a PE ratio of -5.97 and a beta of 1.55. The company has a 50 day moving average price of $6.25 and a two-hundred day moving average price of $6.35.

Inogen (NASDAQ:INGN - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical technology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01. Inogen had a negative return on equity of 13.17% and a negative net margin of 6.94%.The company had revenue of $95.08 million for the quarter, compared to analysts' expectations of $95.23 million. As a group, equities analysts predict that Inogen, Inc will post -0.74 earnings per share for the current fiscal year.

Insider Activity at Inogen

In other news, EVP Boyer Jennifer M. Yi sold 10,938 shares of Inogen stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $6.60, for a total value of $72,190.80. Following the completion of the sale, the executive vice president directly owned 5,039 shares in the company, valued at $33,257.40. The trade was a 68.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 2.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in INGN. BlackRock Inc. purchased a new stake in Inogen in the second quarter worth approximately $11,281,000. Armistice Capital LLC raised its stake in Inogen by 46.3% during the 4th quarter. Armistice Capital LLC now owns 1,264,000 shares of the medical technology company's stock valued at $8,494,000 after buying an additional 400,000 shares during the last quarter. Kent Lake PR LLC lifted its holdings in shares of Inogen by 5.7% during the 2nd quarter. Kent Lake PR LLC now owns 1,061,294 shares of the medical technology company's stock valued at $7,461,000 after buying an additional 57,700 shares during the period. Ameriprise Financial Inc. lifted its holdings in shares of Inogen by 0.8% during the 2nd quarter. Ameriprise Financial Inc. now owns 881,100 shares of the medical technology company's stock valued at $6,194,000 after buying an additional 6,573 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Inogen by 7.9% in the 2nd quarter. Geode Capital Management LLC now owns 615,279 shares of the medical technology company's stock worth $4,326,000 after buying an additional 44,860 shares during the last quarter. Institutional investors own 89.94% of the company's stock.

Inogen Company Profile

Inogen, Inc NASDAQ: INGN is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company's core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen's offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen's flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source